Results 201 to 210 of about 277,119 (298)

Gankyrin‐Protein Interactions in GI Cancers: A Novel Target of New Therapeutics

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Gankyrin (PSMD10) is a 25 kDa oncogenic protein and regulatory subunit of the 26S proteasome, characterized by a sevenfold ankyrin repeat domain. Gankyrin is overexpressed in various malignancies, particularly gastrointestinal (GI) cancers. Gankyrin contributes to tumorigenesis by modulating key signaling pathways and engaging in oncogenic ...
Shuang Li, Yuky Lam, Aaron Muth, Zhe‐Sheng Chen, Shanzhi Wang   +4 more
wiley   +1 more source

A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance

Hepatology Communications, EarlyView., 2022
Abstract Hepatocellular adenomas (HCAs) are benign liver tumors associated with bleeding or malignant transformation. Data on the indication for surgery are scarce. We analyzed indications and outcome of patients operated for HCAs < 50 mm compared to HCAs ≥ 50 mm. Changes in final postoperative diagnosis were assessed.
Martijn P. D. Haring, Arthur K. E. Elfrink, Christiaan A. J. Oudmaijer, Paul C. M. Andel, Alicia Furumaya, Nenke de Jong, Colin J. J. M. Willems, Thijs Huits, Julie M. L. Sijmons, Eric J. T. Belt, Koop Bosscha, Esther C. J. Consten, Mariëlle M. E. Coolsen, Peter van Duijvendijk, Joris I. Erdmann, Paul Gobardhan, Robbert J. de Haas, Tjarda van Heek, Hwai‐Ding Lam, Wouter K. G. Leclercq, Mike S. L. Liem, Hendrik A. Marsman, Gijs A. Patijn, Türkan Terkivatan, Babs M. Zonderhuis, Izaak Quintus Molenaar, Wouter W. te Riele, Jeroen Hagendoorn, Alexander F. M. Schaapherder, Jan N. M. IJzermans, Carlijn I. Buis, Joost M. Klaase, Koert P. de Jong, Vincent E. de Meijer, the Dutch Benign Liver Tumor Group, R. B. Takkenberg, J. Verheij, O. M. van Delden, J. I. Erdmann, B. V. van Rosmalen, A. Furumaya, G. Kazemier, D. Ramsoekh, J. N. M. IJzermans, R. A. de Man, M. D. Doukas, M. G. Thomeer, A. J. Klompenhouwer, A. F. M. Schaapherder, M. E. Tushuizen, M. J. Coenraad, A. S. L. P. Crobach, M. C. Burgmans, S. Feshtali, M. M. E. Coolsen, M. Kramer, J. C. Beckervordersandforth, I. V. Samarska, C. van der Leij, R. Miclea, J. H. W. de Wilt, P. B. van den Boezem, E. T. T. L. Tjwa, I. Munsterman, S. Vos, S. van Koeverden, V. E. de Meijer, F. J. C. Cuperus, R. J. de Haas, E. W. Duiker, M. P. D. Haring   +70 more
wiley   +1 more source

Nanogel‐Mediated Immunotherapy to Tackle Cancer and Inflammatory Diseases

ChemistryEurope, EarlyView.
Nanogels formed through self‐assembly, microemulsion, or precipitation polymerization method enable precise delivery of immunotherapeutic factors and immune cell targeting, thus effectively modulating immune responses. This review highlights recent advances in stimuli‐responsive nanogel design, underlying mechanisms, and their potentials to tackle ...
Ziwen Zhang, Jinxia Wang, Guang‐Zhi Jin, István Bányai, Dzmitry Shcharbin, Ivan Stoikov, Mingwu Shen, Xiangyang Shi   +7 more
wiley   +1 more source

Recent Advances of In Situ Anticancer Nanomedicine from Enzyme‐Instructed Self‐Assembly

ChemNanoMat, EarlyView.
This review summarizes advances in enzymatic self‐assemblies for generating in situ anticancer nanomedicine over the past five years. It highlights the unique features of enzyme substrates for in situ anticancer nanomedicine by discussing the representative examples.
Linrui Zou, Meihui Yi, Bing Xu
wiley   +1 more source

Integrated multi-omics analysis reveals NOL11 as a novel prognostic biomarker for hepatocellular carcinoma. [PDF]

BMC Cancer
Li Z, Fu Y, Wei Y, Zhu Y, Han B, Guo M, Yang J, Xu L, Ye Z, Dong F.   +9 more
europepmc   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source

Synthetic Access to the Class of 3‐Amino‐4‐Cyano‐Substituted Thiophenes

European Journal of Organic Chemistry, EarlyView.
The synthesis of 1,1‐dibromo‐3,4,4‐trichloro‐2‐cyano‐1,3‐butadiene opens a first pathway to 3‐amino‐4‐cyano‐thiophenes. These compounds display a push–pull substitution pattern that allows for selective modifications at the 2 and 5 positions. Through S‐oxidation, substitution, and reduction valuable halo and hydrothiophenes are generated, which could ...
Martin Söftje, Philipp Memmel, Naveed Anwar, Viktor A. Zapol'skii, Mimoza Gjikaj, Eike G. Hübner, Jan C. Namyslo, Dieter E. Kaufmann   +7 more
wiley   +1 more source

CCL20 mediates the effect of cathepsin S on hepatocellular carcinoma development insights from Mendelian randomization and bioinformatics analysis. [PDF]

Discov Oncol
Yuan C, Li Q, Luo M, Liang C, Huang L, Wei L, He Q, Liu Z, Shang L.   +8 more
europepmc   +1 more source

Targeting NAT10 Inhibits Hepatocarcinogenesis via ac4C‐Mediated SMAD3 mRNA Stability

Exploration, EarlyView.
This study demonstrates that elevated N‐acetyltransferase 10 (NAT10) expression stabilizes SMAD3 mRNA through ac4C modification, promoting the progression of hepatocellular carcinoma (HCC). NAT10 also activates the TGF‐β signaling pathway, facilitating epithelial‐to‐mesenchymal transition and inhibiting anoikis. Furthermore, the authors develop a small‐
Yigan Zhang, Yanbin Dong, Shuwen Chen, Hao Deng, Weiru Yu, Bonan Chen, Minjie Chen, Wanglong Liu, Xiao Tan, Jiaxin Ni, Daniel Rigden, Xuan Wang, Wuhua Zhou, Jia Meng, Juan Chen, Yuanchao Xue, Zhongji Meng   +16 more
wiley   +1 more source

Clinical management of liver cancer patients with immune checkpoint inhibitors treatment. [PDF]

Hepat Oncol
Yau JCW, Chan LL, Chan SL.
europepmc   +1 more source